



OFFICIAL PUBLICATION OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

## ONLINE FIRST

This is an Online First, unedited version of this article. The final, edited version will appear in a numbered issue of *CHEST* and may contain substantive changes. We encourage readers to check back for the final article. Online First papers are indexed in PubMed and by search engines, but the information, including the final title and author list, may be updated on final publication.

<http://journal.publications.chestnet.org/>

Online First articles are not copyedited prior to posting.

©American College of Chest Physicians.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.

**Development of Novel Agents for Idiopathic Pulmonary Fibrosis: progress in target selection and clinical trial design**

Thomas O’Riordan, MD<sup>1</sup>, Victoria Smith, PhD<sup>2</sup> and Ganesh Raghu, MD<sup>3</sup>  
Gilead Sciences Inc., Seattle, WA<sup>1</sup> Gilead Sciences Inc., Foster City, CA<sup>2</sup> and University  
of Washington, Seattle, WA<sup>2</sup>

Address for correspondence:  
Ganesh Raghu, MD,  
Director: Center for Interstitial Lung Disease,  
University of Washington,  
1959 NE Pacific Street,  
Seattle, WA 98185

Email: [graghu@uw.edu](mailto:graghu@uw.edu)

Download English Version:

<https://daneshyari.com/en/article/5953725>

Download Persian Version:

<https://daneshyari.com/article/5953725>

[Daneshyari.com](https://daneshyari.com)